binding,il-17a

IL-17 modulator 4 is a prodrug of IL-17 modulator 1 which is an efficacious modulator of IL-17.

IL-17 modulator 3 (US20200247785A1) is a chemical compound that acts as an IL-17 modulator. It has potential applications in researching inflammation, cancer, and autoimmune diseases.

IL-17 Modulator 1 (disodium) is a potent, orally active compound, known for its high efficacy in modulating IL-17. This compound is extensively utilized for researching various diseases such as psoriasis, ankylosing spondylitis, and psoriatic arthritis[1].

IL-17 modulator 5 is a IL-17 inhibitor, with an IC 50 of 1 nM .

(R)-IL-17 modulator 4 is the R-configured form of IL-17 modulator 4 and is a prodrug of IL-17 modulator 1. IL-IL-17 modulator 1 is a potent, orally active IL-17 modulator.

IL-17 modulator 4 sulfate is a prodrug of IL-17 modulator 1 . IL-17 modulator 1 is an orally active, highly efficacious IL-17 modulator.

STK630921 is a blocker of IL-17A binding to the IL-17A receptor (IL-17RA).

GSK2981278 (ROR gama modulator 1) is a highly potent and selective inverse agonist of retinoic acid receptor-related orphan receptor gamma (ROR gamma).

Vunakizumab is a humanized IgGκ monoclonal antibody targeting IL-17A, which is often linked to interleukin 22 to form Vunakizumab-IL22 for the study of influenza virus-induced lung immune injury Vunakizumab is used in the study of psoriatic arthritis and works by binding to IL-17A.

Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A with a Kd value of <3 pM.Ixekizumab blocks the binding of IL-17A to IL-17RA but not to other IL-17 family members.Ixekizumab is used for the treatment of moderate to severe plaque psoriasis, psoriasis, arthritis and psoriasis. arthritis, and psoriasis.